Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivation

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33438-33455

  Kresty, Laura A ^a   Weh, Katherine M ^a   Zeyzus Johns, Bree ^a   Perez, Laura N ^a   Howell, Amy B ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Autophagy; Bile acid; Cranberry proanthocyanidins; Esophageal adenocarcinoma; PI3K AKT mTOR

Indexed keywords

CASPASE; CYTOCHROME C; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROANTHOCYANIDIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ENZYME INHIBITOR; ONCOPROTEIN; PLANT EXTRACT; TARGET OF RAPAMYCIN KINASE;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CRANBERRY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ESOPHAGEAL ADENOCARCINOMA; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD50; MALE; MOUSE; NONHUMAN; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ESOPHAGUS TUMOR; ISOLATION AND PURIFICATION; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PLANT EXTRACTS; PROANTHOCYANIDINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VACCINIUM MACROCARPON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946029088     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5586     Document Type: Article

References (57)

1. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008; 100: 1184-1187.
2. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009; 58: 182-188.
3. American Cancer Society (2015) Cancer Facts and Figures. Atlanta: American Cancer Society; 2015.
4. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007; 17: 2-9.
5. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005; 143: 199-211.
6. Washington DC: American Institute for Cancer Research;2007. World Cancer Research Fund/American Institute for Cancer Research: Food, nutrition, physical activity, and prevention of cancer: A global perspective.
7. Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Corley DA. Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am Gastroenterol. 2008; 103: 1614-1623.
8. Bravi F, Edefonti V, Randi G, Ferraroni M, La Vecchia C, Decarli A. Dietary patterns and upper aerodigestive tract cancers: an overview and review. Ann Oncol. 2012; 23: 3024-3948.
9. Howell AB, Botto H, Combescure C. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010; 10: 94.
10. Krueger CG, Reed JD, Feliciano RP, Howell AB. Quantifying and characterizing proanthocyanidins in cranberries in relation to urinary tract health. Anal Bioanal Chem. 2013; 405: 4385-4395.
11. Foo LY, Lu Y, Howell AB, Vorsa N. The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro. Phytochemistry 2000; 54: 173-181.
12. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial antiadhesion activity. Phytochemistry. 2005; 66: 2281-2291.
13. Kasper KL, Howell AB, Khoo C. A randomized doubleblind, placebo-controlled trial to assess the bacterial antiadhesion effects of cranberry extract beverages. Food Funct. 2015; 6: 1212-1217.
14. Pappas E, Schaich KM. Phytochemicals of cranberries and cranberry products: Characterization, potential health effects, and processing stability. Crit Rev Food Sci Nutr. 2009; 49: 741-781.
15. Neto CC. Cranberries: ripe for more cancer research? J Sci Food Agric. 2011; 91: 2303-2307.
16. Kresty LA, Howell AB, Baird M. Cranberry proanthocyanidins mediate growth arrest of lung cancer cells through modulation of gene expression and rapid induction of apoptosis. Molecules. 2011; 16: 2375-2390.
17. Kresty LA, Howell AB, Baird M. Cranberry proanthocyanidins induce apoptosis and inhibit acidinduced proliferation of human esophageal adenocarcinoma cells. J Agric Food Chem. 2008; 56: 676-680.
18. Kresty LA, Clarke J, Ezell K, Exum A, Howell AB, Guettouche T. MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention. J Carcinog. 2011; 10: 34.
19. Déziel B, MacPhee J, Patel K, Catalli A, Kulka M, Neto C, Gottschall-Pass K, Hurta R. American cranberry (Vaccinium macrocarpon) extract affects human prostate cancer cell growth via cell cycle arrest by modulating expression of cell cycle regulators. Food Funct. 2012; 3: 556-564.
20. Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG. Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol. 2012; 40: 227-235.
21. Liu M, Lin LQ, Song BB, Wang LF, Zhang CP, Zhao JL, Liu JR. Cranberry phytochemical extract inhibits SGC-7901 cell growth and human tumor xenografts in Balb/c nu/nu mice. J Agric Food Chem. 2009; 57: 762-768.
22. Evans S, Dizeyi N, Abrahamsson PA, Persson J. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models. Anticancer Res. 2009; 29: 3917-3924.
23. Ferguson PJ, Kurowska EM, Freeman DJ. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutr Cancer. 2006; 56: 86-94.
24. Boateng J, Verghese M, Shackelford L, Walker LT, Khatiwada J, Ogutu S, Williams DS, Jones J, Guyton M, Asiamah D, Henderson F, Grant L, DeBruce M, et al. Selected fruits reduce azoxymethane (AOM)-induced aberrant crypt foci (ACF) in Fisher 344 male rats. Food Chem Toxicol. 2007; 45: 725-732.
25. Prasain JK, Jones K, Moore R, Barnes S, Leahy M, Roderick R, Juliana MM, Grubbs CJ. Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers. Oncol Rep. 2008; 19: 1565-1570.
26. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, Parry JM. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-κB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis. 2004; 25: 317-323.
27. Bernstein H, Berstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol. 2009; 15: 3329-3340.
28. Dvorakova K, Payne CM, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner RE, Riley C, Prasad A, Garewal H. Apoptosis resistance in Barrett's esophagus:ex vivo bioassay of live stressed tissues. Am J Gastroenterol. 2005; 100: 424-431.
29. Goldman A, Chen HD, Roesly HB, Hill KA, Tome ME, Dvorak B, Bernstein H, Dvorak K. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G292-302.
30. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, Chen CT, Kuo HP, Hsu JM, Sun HL, Chou CK, Buttar NS, Wang KK, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 2008; 68: 2632-2640.
31. Abdel-Latif MM, Kelleher D, Reynolds JV. Molecular mechanisms of constitutive and inducible NF-kappaB activation in oesophageal adenocarcinoma. Eur J Cancer. 2015; 51: 464-472.
32. Boonstra JJ, Marion RV, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 2010; 102: 271-274.
33. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001; 96: 2839-2848.
34. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, Wild CP. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006; 55: 1390-1397.
35. Fichter CD, Herz C, Münch C, Opitz OG, Werner M, Lassmann S. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells. BMC Cell Biol. 2011; 12: 13.
36. Alvarez H, Koorstra JB, Hong SM, Boonstra JJ, Dinjens WN, Foratiere AA, Wu TT, Montgomery E, Eshleman JR, Maitra A. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther. 2008; 7: 1753-1755.
37. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTor pathways in cells. Proc Natl Acad Sci USA. 2005; 102: 8204-8209.
38. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pientenpol JA. A gene signature based approach identifies mTOR as a regulator of p73. Mol Cell Biol. 2008; 28: 5951-5964.
39. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO. Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways? J Signal Transduct. 2011; 2011: 792639.
40. Kirkland JB. Poly ADP-ribose polymerase-1 and health. Exp Biol Med. 2010; 235: 561-568.
41. Halicka HD, Zhao H, Li J, Lee YS, Hsieh TC, Wu JM, Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive mTOR-and DNA damage-signaling. Aging (Albany, NY). 2012; 4: 952-965.
42. Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATMmediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol. 2012; 83: 747-757.
43. Deverman BE, Cook BL, Manson SR, NiederhoffRA, Langer EM, Rosová I, Kulans LA, Fu X, Weinberg JS, Heinecke JW, Roth KA, Weintraub SJ. Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell. 2002; 111: 51-62.
44. Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol. 2007; 5: 39-53.
45. Reid BJ, Li X, Galipeau P, Vaughen TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Reviews Cancer. 2010; 10: 87-101.
46. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ. 2008; 15: 1318-1329.
47. Niso-Santano M, Bravo-San Pedro JM, Maiuri MC, Tavernarakis N, Cecconi F, Madeo F, Codogno P, Galluzzi L, Kroemer G. Novel inducers of BECN1-independent autophagy: cis-unsaturated fatty acids. Autophagy. 2015; 11: 575-577.
48. Paterson AL, Shannon NB, Lao-Sirieix P, Ong CA, Peters CJ, O'Donovan M, Fitzgerald RC. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut. 2013; 62: 1415-1424.
49. Tasioudi KE, Sakellariou S, Levidou G, Theodorou D, Michalopoulos NV, Patsouris E, Korkolopoulou P, Saetta AA. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. APMIS. 2015; 123: 639-647.
50. Prins MJ, Verhage RJ, Ruurda JP, ten Kate FJ, van Hillegersberg R. Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol. 2013; 66: 224-228.
51. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009; 27: 857-871.
52. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res. 2007; 13: 659-665.
53. von Holzen U, Chen T, Boquoi A, Richter JE, Falk GW, Klein-Szanto AJ, Cooper H, Litwin S, Weinberg DS, Enders GH. Evidence for DNA damage checkpoint activation in Barrett esophagus. Transl Oncol. 2010; 3: 33-42.
54. Roesly HB, Khan MR, Chen HD, Hill KA, Narendran N, Watts GS, Chen X, Dvorak K. The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G864-G872.
55. Chen Y, Lu Y, Lu C, Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxiainducible factor (HIF)-1a expression. Pathol Oncol Res. 2009; 15: 487-493.
56. Dho SH, Deverman BE, Lapid C, Manson SR, Gan L, Riehm JJ, Aurora R, Kwon KS, Weintraub SJ. Control of cellular Bcl-xL levels by deamidation-regulated degradation. PLoS Biol. 2013; 11: e1001588.
57. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009; 69:3364-73.